Quality by design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and their related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody (MAb). This chapter describes the tools used for the characterization and validation of MAb manufacturing process under the QbD paradigm. This comprises risk assessments for the identification of potential Critical Process Parameters (pCPPs), statistically designed experimental studies as well as studies assessing the linkage of the unit operations. Outcome of the studies is the classification of process parameters according to their criticality and the definition of appropriate acceptable ranges of operation. The process and product knowledge gained in these studies can lead to the approval of a Design Space. Additionally, the information gained in these studies are used to define the 'impact' which the manufacturing process can have on the variability of the CQAs, which is used to define the testing and monitoring strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biologicals.2016.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling per- and polyfluoroalkyl substances contamination in e-cigarette refill liquids: A comprehensive analytical assessment.
Sci Total Environ
January 2025
Department of Analytical Chemistry, Faculty of Chemistry, Gdańsk University of Technology (GUT), ul. G. Narutowicza 11/12, 80-233 Gdańsk, Poland; EcoTech Center, Gdańsk University of Technology (GUT), ul. G. Narutowicza 11/12, 80-233 Gdańsk, Poland.
A robust analytical method was developed for the determination of per- and polyfluoroalkyl substances (PFAS) in e-cigarette refill liquids using solid-phase extraction (SPE) with weak anion-exchange sorbent, followed by detection with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The design of experiment approach was employed to optimize sample preparation, leading to the validation of the method with limits of detection for PFAS ranging from 0.24 to 1.
View Article and Find Full Text PDFSurface display and characterization of recombinant α-l-Rhamnosidase from Emiliania huxleyi on Pichia pastoris.
Bioorg Chem
January 2025
Guangdong Provincial Key Laboratory of Lingnan Specialty Food Science and Technology, Zhongkai University of Agriculture and Engineering, Guangzhou 510225, China; Key Laboratory of Green Processing and Intelligent Manufacturing of Lingnan Specialty Food, Ministry of Agriculture, Zhongkai University of Agriculture and Engineering, Guangzhou 510225, China.
An α-l-Rhamnosidase gene with an open reading frame of 3192 bp encoding a 1036-amino acid protein (EhRha) was cloned from Emiliania huxleyi for flavonoid hydrolysis on the cell surface of Pichia pastoris (P. pastoris) strain GS115 by fusing with the anchor protein (AGα1) from Saccharomyces cerevisiae. Fluorescence microscopy and flow cytometry assays revealed that EhRha was successfully displayed on the cell surface of P.
View Article and Find Full Text PDFThe future of cell-free synthetic biology.
Biotechnol Notes
November 2024
Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.
Cell-free synthetic biology aims at the targeted replication, design, and modification of life processes in open systems by breaking free of constraints such as cell membrane barriers and living cell growth. The beginnings of this systematized technology, which took place in the last century, were used to explore the secrets of life. Currently, with its easy integration with other technologies or disciplines, cell-free synthetic biology is developing into a powerful and effective means of understanding, exploiting, and extending the structure and function of natural living systems.
View Article and Find Full Text PDFGlucagon-like peptide-1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes, yet established peptide-based therapies require injections and complex manufacturing. Small-molecule GLP1RAs promise oral bioavailability and scalable manufacturing, but their selective binding to human versus rodent receptors has limited mechanistic studies. The neural circuits through which these emerging therapeutics modulate feeding behavior remain undefined, particularly in comparison to established peptide-based GLP1RAs.
View Article and Find Full Text PDFApplications of genetic code expansion in live cells are widespread and continually emerging, yet they have been limited by their reliance on the supplementation of non-standard amino acids (nsAAs) to cell culturing media. While advances in cell-free biocatalysis are improving nsAA synthesis cost and sustainability, such processes remain reliant on multi-step processes of product isolation followed by supplementation to engineered cells. Here, we report the design of a modular and genetically encoded system that combines the steps of biosynthesis of diverse phenylalanine derivatives, which are the most frequently used family of nsAAs for genetic code expansion, and their site-specific incorporation within target proteins using a single engineered bacterial host.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!